Healthcare Roundup – Regeneron +2.3% after Trump praises drug, Aprea on go with early-stage study with APR-548

Published on: October 8, 2020
Author: Amy Liu

Regeneron +2.3% after Trump praises drug in new video

Regeneron (NASDAQ:REGN) is on the move, up 2.3% postmarket, after a callout of its drug as “the key” in President Trump’s latest video, posted directly to his Twitter feed.

“I went in, I wasn’t feeling so hot, and within a very short period of time they gave me Regeneron – and other things too, but I think this was the key,” Trump says in the video. “I felt good immediately.”

NAI500 seeks to provide the most pressing investment knowledge to its readers. On October 7 and 8, NAI500 is hosting a FREE VIRTUAL EVENT focusing on the rapidly growing mining sector. Learn about Gold and Precious Metals Exploration, Battery Metals and much more by registering here.

“I view these – they called them therapeutic, but to me it wasn’t therapeutic, it just made me better. OK? I call that a cure.”

He alluded to getting therapies like Regeneron’s antibody cocktail to Americans for free, after the election.

Having freshly returned from Walter Reed hospital, Trump returned to work in the Oval Office today for a briefing on stimulus talks and hurricanes.

Updated 6:11 p.m.: President Trump also mentioned Eli Lilly (NYSE:LLY) in his video; its shares are up 1.6% after hours.

Aprea on go with early-stage study with APR-548 in blood disorder

The FDA has signed-off the Phase 1 trial of Aprea Therapeutics’ (NASDAQ:APRE) APR-548 for the treatment of TP53 mutant myelodysplastic syndromes.

APR-548 is a small molecule reactivator of mutant p53 that is being developed for oral administration.

Bristol Myers’ ozanimod OK’d in Canada for multiple sclerosis

Health Canada approves Bristol Myers Squibb’s (NYSE:BMY) Zeposia (ozanimod) for the treatment of patients with relapsing remitting multiple sclerosis to decrease the frequency of clinical exacerbations.

The FDA approved it in March.

Lilly teams up with DexCom for diabetes management

Eli Lilly (NYSE:LLY) and DexCom (NASDAQ:DXCM) announce a joint program for U.S. healthcare providers (HCPs) about Lilly’s new rapid-acting mealtime insulin Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), now available in U.S. pharmacies, and Dexcom G6 CGM Systems.

The program is designed to help clinicians use data to inform diabetes management, including giving visibility to the benefits of a new mealtime insulin.

HCPs treating type 1 and type 2 diabetes will be able to assess their patients’ glucose levels and time in range with Dexcom G6 or Dexcom G6 Pro, helping them to manage postprandial glucose levels.

Philips partners with LeQuest to provide e-training in ultrasound

Royal Philips (NYSE:PHG) and LeQuest announced a partnership to provide online interactive training for the Philips Ultrasound Affiniti system.

The Affiniti system offers healthcare professionals a powerful combination of performance and workflow for quick and efficient diagnosis with low operating cost, providing exceptional image quality across applications such as radiology, obstetrics & gynecology, and cardiology.

“Partnering with LeQuest enables us to further expand our offering of solutions that aid in optimizing the healthcare ecosystem,” said Bich Le, Senior Vice President and General Manager Ultrasound at Philips. “As the role of ultrasound continues to expand, new capabilities, such as remote clinical collaboration and virtual training, have been particularly valuable during the COVID-19 pandemic, enabling providers to reduce in-person contact and reduce infection risk.”

Biotechnology Healthcare Services Life Science Medical Device Pharmaceutical